Bristol Myers Squibb invested $20 million in Compugen. In return, the company received 2,332,815 shares of Compugen stock at $8.57333 per share, a 33% premium over the Nov. 9, 2021 closing price. In addition, as part of the expanded collaboration, a joint committee was formed to strategically manage Compugen's COM701 anti-tumor antibody clinical research programs.